Andrew covers the biopharma industry, scientific research, and public health across the continent. You can reach Andrew confidentially on Signal at drewqjoseph.71. LONDON — GSK on Monday said that ...

GSK's CEO Emma Walmsley will step down in December and be replaced by insider Luke Miels, the British drugmaker said on Monday, tasking the new leader to deliver shareholder value and prepare for the ...

GSK GSK-2.07%decrease; red down pointing triangle said Chief Executive Emma Walmsley would step down and be succeeded by commercial chief Luke Miels, as the drugmaker works to replenish its product ...

(Reuters) -GSK's CEO Emma Walmsley will step down at the end of the year and be replaced by insider Luke Miels, the drugmaker said on Monday, a surprise switch as the British firm looks to rev up its ...

In his first investor update as GSK’s CEO, Luke Miels defined a core of his vision for the company’s next chapter: “We need to be more product-centric as a company.” Being product-centric means ...

The first woman to helm a Big Pharma will be stepping down in January as GSK’s Emma Walmsley moves aside for her chief commercial officer Luke Miels. Walmsley, 56, who became the British pharma’s CEO ...

When it comes to GSK’s new dealmaking strategy of trying to outdo established blockbusters, CEO Luke Miels has told Fierce that oncology may offer the most tempting targets. Miels—who served as GSK’s ...

GSK (GSK) announces that Luke Miels is appointed CEO Designate, GSK. He will assume full responsibilities as CEO and join the Board on 1st January 2026. Miels joined GSK in 2017 and is currently Chief ...

LONDON (Reuters) - Doing things one at a time in drug development is not a luxury that GlaxoSmithKline can afford any longer, the head of pharmaceuticals at Britain's largest drugmaker told Reuters.

(Reuters) -GSK raised its 2025 sales and earnings expectations on Wednesday after third-quarter results beat forecasts, helped by double-digit growth for its HIV and cancer drugs. This is CEO Emma ...